These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

888 related items for PubMed ID: 31243151

  • 1. Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer.
    Zhao N, Peacock SO, Lo CH, Heidman LM, Rice MA, Fahrenholtz CD, Greene AM, Magani F, Copello VA, Martinez MJ, Zhang Y, Daaka Y, Lynch CC, Burnstein KL.
    Sci Transl Med; 2019 Jun 26; 11(498):. PubMed ID: 31243151
    [Abstract] [Full Text] [Related]

  • 2. Exploiting Dependence of Castration-Resistant Prostate Cancer on the Arginine Vasopressin Signaling Axis by Repurposing Vaptans.
    Heidman LM, Peinetti N, Copello VA, Burnstein KL.
    Mol Cancer Res; 2022 Aug 05; 20(8):1295-1304. PubMed ID: 35503085
    [Abstract] [Full Text] [Related]

  • 3. Targeting AR Variant-Coactivator Interactions to Exploit Prostate Cancer Vulnerabilities.
    Magani F, Peacock SO, Rice MA, Martinez MJ, Greene AM, Magani PS, Lyles R, Weitz JR, Burnstein KL.
    Mol Cancer Res; 2017 Nov 05; 15(11):1469-1480. PubMed ID: 28811363
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
    Thamilselvan V, Menon M, Thamilselvan S.
    Int J Cancer; 2016 Oct 01; 139(7):1632-47. PubMed ID: 27198552
    [Abstract] [Full Text] [Related]

  • 6. Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer.
    Moon SJ, Jeong BC, Kim HJ, Lim JE, Kim HJ, Kwon GY, Jackman JA, Kim JH.
    Theranostics; 2021 Oct 01; 11(2):958-973. PubMed ID: 33391515
    [Abstract] [Full Text] [Related]

  • 7. Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.
    Cao Q, Song Z, Ruan H, Wang C, Yang X, Bao L, Wang K, Cheng G, Xu T, Xiao W, Xiong Z, Liu D, Yang M, Zhou D, Yang H, Chen K, Zhang X.
    Clin Cancer Res; 2020 Mar 15; 26(6):1516-1528. PubMed ID: 31796514
    [Abstract] [Full Text] [Related]

  • 8. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.
    Hoang DT, Iczkowski KA, Kilari D, See W, Nevalainen MT.
    Oncotarget; 2017 Jan 10; 8(2):3724-3745. PubMed ID: 27741508
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Lee CH, Ku JY, Ha JM, Bae SS, Lee JZ, Kim CS, Ha HK.
    Prostate; 2017 Jan 10; 77(1):60-71. PubMed ID: 27550197
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
    Nakata D, Nakayama K, Masaki T, Tanaka A, Kusaka M, Watanabe T.
    Prostate; 2016 Dec 10; 76(16):1536-1545. PubMed ID: 27473672
    [Abstract] [Full Text] [Related]

  • 14. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.
    Sharp A, Coleman I, Yuan W, Sprenger C, Dolling D, Rodrigues DN, Russo JW, Figueiredo I, Bertan C, Seed G, Riisnaes R, Uo T, Neeb A, Welti J, Morrissey C, Carreira S, Luo J, Nelson PS, Balk SP, True LD, de Bono JS, Plymate SR.
    J Clin Invest; 2019 Jan 02; 129(1):192-208. PubMed ID: 30334814
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Melatonin Inhibits Androgen Receptor Splice Variant-7 (AR-V7)-Induced Nuclear Factor-Kappa B (NF-κB) Activation and NF-κB Activator-Induced AR-V7 Expression in Prostate Cancer Cells: Potential Implications for the Use of Melatonin in Castration-Resistant Prostate Cancer (CRPC) Therapy.
    Liu VWS, Yau WL, Tam CW, Yao KM, Shiu SYW.
    Int J Mol Sci; 2017 May 31; 18(6):. PubMed ID: 28561752
    [Abstract] [Full Text] [Related]

  • 19. A natural molecule, urolithin A, downregulates androgen receptor activation and suppresses growth of prostate cancer.
    Dahiya NR, Chandrasekaran B, Kolluru V, Ankem M, Damodaran C, Vadhanam MV.
    Mol Carcinog; 2018 Oct 31; 57(10):1332-1341. PubMed ID: 30069922
    [Abstract] [Full Text] [Related]

  • 20. SC912 inhibits AR-V7 activity in castration-resistant prostate cancer by targeting the androgen receptor N-terminal domain.
    Yi Q, Han X, Yu HG, Chen HY, Qiu D, Su J, Lin R, Batist G, Wu JH.
    Oncogene; 2024 May 31; 43(20):1522-1533. PubMed ID: 38532114
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.